Use of Insulin Sensitizers in NASH

Mouen Khashab; Naga Chalasani

doi:10.1016/j.ecl.2007.07.006

Use of Insulin Sensitizers in NASH

Research output: Contribution to journal › Review article › peer-review

Abstract

This article briefly discusses nonalcoholic fatty liver disease (NAFLD) and its association with the metabolic syndrome, its pathogenesis and natural history. It then presents a detailed discussion on the efficacy and safety of different insulin sensitizers in patients who have NASH.

Original language	English (US)
Pages (from-to)	1067-1087
Number of pages	21
Journal	Endocrinology and metabolism clinics of North America
Volume	36
Issue number	4
DOIs	https://doi.org/10.1016/j.ecl.2007.07.006
State	Published - Dec 2007
Externally published	Yes

ASJC Scopus subject areas

Endocrinology, Diabetes and Metabolism
Endocrinology

Access to Document

10.1016/j.ecl.2007.07.006

Cite this

@article{9c3a2ca572f04eab8cb81ce0084c2f15,

title = "Use of Insulin Sensitizers in NASH",

abstract = "This article briefly discusses nonalcoholic fatty liver disease (NAFLD) and its association with the metabolic syndrome, its pathogenesis and natural history. It then presents a detailed discussion on the efficacy and safety of different insulin sensitizers in patients who have NASH.",

author = "Mouen Khashab and Naga Chalasani",

year = "2007",

month = dec,

doi = "10.1016/j.ecl.2007.07.006",

language = "English (US)",

volume = "36",

pages = "1067--1087",

journal = "Endocrinology and Metabolism Clinics of North America",

issn = "0889-8529",

publisher = "W.B. Saunders Ltd",

number = "4",

}

TY - JOUR

T1 - Use of Insulin Sensitizers in NASH

AU - Khashab, Mouen

AU - Chalasani, Naga

PY - 2007/12

Y1 - 2007/12

N2 - This article briefly discusses nonalcoholic fatty liver disease (NAFLD) and its association with the metabolic syndrome, its pathogenesis and natural history. It then presents a detailed discussion on the efficacy and safety of different insulin sensitizers in patients who have NASH.

AB - This article briefly discusses nonalcoholic fatty liver disease (NAFLD) and its association with the metabolic syndrome, its pathogenesis and natural history. It then presents a detailed discussion on the efficacy and safety of different insulin sensitizers in patients who have NASH.

UR - http://www.scopus.com/inward/record.url?scp=35648951688&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35648951688&partnerID=8YFLogxK

U2 - 10.1016/j.ecl.2007.07.006

DO - 10.1016/j.ecl.2007.07.006

M3 - Review article

C2 - 17983937

AN - SCOPUS:35648951688

VL - 36

SP - 1067

EP - 1087

JO - Endocrinology and Metabolism Clinics of North America

JF - Endocrinology and Metabolism Clinics of North America

SN - 0889-8529

IS - 4

ER -

Use of Insulin Sensitizers in NASH

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this